From The Editor | May 14, 2013

Australia Welcomes Custom Mammalian-Based Biopharmaceutical Manufacturing

DSM Pharmaceutical Products announced at Bio International 2013 that its’ new cGMP custom biopharmaceutical manufacturing  ‘biologics plant of the future’ was set to open in June 2013 in Brisbane, Australia. The facility will be adjacent to the Translational Research Institute of Queensland, Australia’s comprehensive medical research and biopharmaceutical facility located on the Princess Alexandra Hospital campus.

The state-of-the-art commercial and development facility was built with the cooperation of the Queensland and Commonwealth Governments of Australia. Australia currently has a vibrant biotech industry but no custom mammalian-based biopharmaceutical manufacturing operation. Biopharmaceuticals Australia (BPA), which was formed by the Queensland government, partnered with DSM to bring the facility and operation to Brisbane.

access the From The Editor!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)